36,776 results on '"TRIPLE-negative breast cancer"'
Search Results
2. Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer (TNBC-RT2023)
3. A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
4. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR
5. A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
6. Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
7. Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
8. Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
9. Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (ETNA)
10. Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT)
11. Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE)
12. Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
13. Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
14. Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
15. INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
16. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
17. Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models
18. EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer
19. Targeting tumor–stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model
20. A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
21. A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)
22. A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR)
23. Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)
24. AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
25. Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
26. Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
27. Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01)
28. CTS2190 Phase I /II Clinical Study in Patients
29. Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
30. A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer (NeoATCT)
31. A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
32. START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
33. Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)
34. Multicore iron oxide nanoparticles for magnetic hyperthermia and combination therapy against cancer cells.
35. Role of flavonoids in inhibiting triple-negative breast cancer.
36. Cytotoxic properties, glycolytic effects and high-resolution respirometry mitochondrial activities of Eriocephalus racemosus against MDA-MB 231 triple-negative breast cancer.
37. Efficient separation of large particles and giant cancer cells using an isosceles trapezoidal spiral microchannel.
38. TRPS1, a sensitive marker for different histological and molecular types of breast cancer.
39. lncRNA CYTOR 靶向 miR-139-5p 对三阴性 乳腺癌细胞增殖的影响及其机制.
40. The role of the miR-30a-5p/ BCL2L11 pathway in rosmarinic acid-induced apoptosis in MDAMB-231-derived breast cancer stem-like cells.
41. Low-pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple-negative breast cancer.
42. The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date).
43. Modulation of programmed death‐ligand 1 expression to augment sensitivity to atezolizumab in breast cancer cells through nonthermal air gas plasma.
44. Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer.
45. Artificial intelligence enhances whole‐slide interpretation of PD‐L1 CPS in triple‐negative breast cancer: A multi‐institutional ring study.
46. Carbon nanotubes conjugated with cisplatin activate different apoptosis signaling pathways in 2D and 3D-spheroid triple-negative breast cancer cell cultures: a comparative study.
47. Expression of programmed death ligand 1 in patients with triple-negative breast cancer: Association with clinicopathological parameters.
48. PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti–PD-1 immunotherapy.
49. EP300 promotes tumor stemness via epigenetic activation of CRISP3 leading to lobaplatin resistance in triple-negative breast cancer.
50. Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.